



intrasense®

Press
release

Montpellier, France, September 30th 2020 – after market close

HY 2020 Consolidated Results Intrasense Group

- **EBITDA at + € 106k**
- **Turnover Growth 10.1%**
- **Cash position strengthened at + € 2,631k€**

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and Myrian® designer, announces its 2020 consolidated IFRS half-year results at Group level as of June 30, 2020.

As announced in the press release dated July 13th, 2020 relating to the mother company's half-year financial statements, Intrasense is now communicating its consolidated financial statements in accordance with IFRS standards, presenting therefore a comprehensive view of the Group's economic performance.

Moderate impact of the health crisis

Intrasense has been impacted by the global health crisis and particularly on the European and Chinese markets with a limitation of its commercial activities. The Group was able to mitigate the challenge posed by this exceptional situation both by supporting the medical teams worldwide by providing of a specific COVID-19 application but also by maintaining its results.

A strategy that continues to be successful

The Group's consolidated half-year results allow Intrasense to achieve its EBITDA balance target with a positive EBITDA of + € 106k as of June 30th, 2020 (versus - € 191k in H1 2019).

IFRS consolidated figures ⁽¹⁾

Figures in (k€)	S1 2020	S1 2019	Evolution
Turnover	1,581	1,436	+10,1%
EBITDA	106	-191	n.a
Cash and equivalents	2,631	773	n.a



Intrasense Group strategy enables a turnover growth compared to the first half of 2019. At Group level, Intrasense generates + € 1,581k turnover, a 10.1 % growth thanks to China's outperformance which was released from COVID-19 lock down earlier than Europe. The Group has also strengthened its independence with strong Cash and equivalents as of June 30th, 2020, with + € 2,631k.

Pursuit of the industrial strategy and outlook

As announced in recent months, Intrasense continues to implement its industrial strategy, based on its pillars such as innovation for medical value and commercial development in Europe and China. In this context, targeted investments might be considered to accelerate corporate growth and become a world leader in its field.

The COVID-19 epidemic is still strongly present globally. In this context, the company has now included its dedicated solution, which had been launched as early as March 2020 as a world premiere, in its commercial catalog with the aim of continuing its deployment. An independent scientific study⁽²⁾ published in the International Journal of Environmental Research and Public Health ranked Intrasense' solution as one of the best on the market, securing the company's industrial lead and visibility in this area.

The enrichment of the Myrian® platform continues to accelerate with the release of the 2.8 version, incorporating many innovations and new clinical applications, such as tomosynthesis which is a high resolution imaging solution widely used in breast cancer screening process. These developments reinforce Myrian®'s attractiveness.



About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian® more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

(1) Intrasense Group Half Year IFRS Consolidated accounts, unaudited

(2) Chest CT Computerized Aided Quantification of PNEUMONIA Lesions in COVID-19 Infection: A Comparison among Three Commercial Software. *International Journal of Environmental Research and Public Health*. 2020; 17(18):6914.

Contacts

Intrasense
Jérémie Peyron
Marketing & Communication manager
1231 avenue du Mondial 98, 34000
Montpellier, FRANCE
Tel: +334 67 130 130
investor@intrasense.fr

NewCap
Investor Relations and Financial
Communication
Roxane Gbedigro
Paris, FRANCE
Tel: +331 44 71 20 43
intrasense@newcap.eu

